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Abstract
Migraine is a common, chronic disorder of the brain causing much disability, as well as personal, familial and societal
impact. Several oral preventive agents are available in different countries for the prevention of migraine, but none have
performed better than 50 % improvement in 50 % of patients in a clinical trial. Additionally, each has various possible
adverse events making their tolerability less than optimal. Recently, three monoclonal antibodies targeting the calcitonin
gene-related peptide (CGRP) ligand (LY2951742, ALD403 and TEV-48125) and one targeting the CGRP receptor (AMG 334)
have completed phase 2 trials, and the results have been reported. These early results show them all to be somewhat
more effective than placebo, with no serious adverse events. Three have been studied for episodic migraine, and only
TEV-48125 has been studied for both high frequency episodic and chronic migraine. Moreover, preliminary data suggests
that neurostimulation is effective in migraine treatment, including stimulation of the sphenopalatine ganglion,
transcutaneous supraorbital and supratrochlear nerve, and transcutaneous vagus nerve. In this article, these
innovative therapies will be reviewed.
Keywords: Migraine, Cluster headache, Prevention, CGRP, Monoclonal antibodies, Neurostimulation, Neuromodulation,
Vagus nerve stimulation, Supraorbital and supratrochlear nerve stimulation
Background
Migraine is a common, chronic neurovascular disorder of
the brain with cranial autonomic findings. It is character-
ized by recurrent, severe attacks of headaches often asso-
ciated with other symptoms and much disability, as well
as personal, familial and societal impact. It affects approxi-
mately 12 % of the general population in Western coun-
tries, and affects three times more women than men [1].
Migraine disability is related to the frequency and severity
of attacks together with the number and type of existing
comorbidities. Mood disorders, obesity and medication
overuse are the most common co-occurring chronic disor-
ders that significantly amplify the impact of migraine on
the individual [2, 3].
Migraine attacks are episodic and average 1–3 times per
month in most migraineurs. Chronic migraine is defined
as headaches on at least 15 days per month for at least
3 months in patients with a history of episodic migraine.
Additionally, patients must present features of migraine on
at least 8 days per month. Up to 30 % of migraineurs have
an aura preceding or coexisting with the headache, which
is usually a visual aberration lasting about 20 minutes,
but could be paresthesias on one side of the body or
speech arrest [4].
Patients with episodic migraine can remit, remain un-
changed, or progress to high-frequency episodic or chronic
migraine over time. Chronic migraine is associated with a
substantially greater personal and societal burden, an in-
creased number of comorbidities, and patients may de-
velop progressive brain abnormalities [5–7]. Migraine is a
serious and widespread health problem as measured by
years lived with disability (YLDs) and is considered the
sixth highest cause of disability worldwide, while medica-
tion overuse headaches follow at eighteenth [8]. By adding
these two conditions together, headache becomes the
third most common cause of disability measured in
YLDs worldwide [9].
All migraineurs require acute care treatment, and up
to 40 % of episodic migraineurs could benefit from pre-
ventive therapy; but few undertake it. Poor quality of life
is one of the various appropriate reasons to start a pa-
tient on migraine preventive therapy. All patients with
* Correspondence: dimosmitsikostas@icloud.com
1Neurology Department, Athens Naval Hospital, 70 Dinokratous Street, 11521
Athens, Greece
Full list of author information is available at the end of the article
Controversies in Neurology
© 2015 Mitsikostas and Rapoport. Open Access This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Mitsikostas and Rapoport BMC Medicine  (2015) 13:279 
DOI 10.1186/s12916-015-0522-1
chronic migraine should be offered prevention to attempt
to reduce the number and severity of their headache days.
Currently, oral pharmaceutical agents are recommended as
the first choice for preventive migraine treatment world-
wide and invasive treatments are suggested only occasion-
ally [10–12].
The main goals of migraine preventive treatment in-
clude: reducing headache frequency, severity and inten-
sity; restoring function; and preventing progression to
chronic migraine. There is evidence that valproate, topir-
amate, metoprolol, propranolol, timolol and flunarizine
are effective for episodic migraine prevention and should
be offered to appropriate migraineurs to reduce migraine
attack frequency and severity (level A medications) [10].
Frovatriptan (primarily indicated and usually used for
acute care of migraine) is effective for prevention of
menstrual migraine (level A), while lamotrigine is inef-
fective for migraine prevention and should not be used
(level A) [10–12]. Although commonly used in clinical
practice, amitriptyline does not carry adequate evidence
for migraine prevention (only class II studies) [10]. For
prevention of chronic migraine (with and without medica-
tion overuse) only one treatment is approved in the US by
the Food and Drug Administration (FDA) and that is ona-
botulinumtoxinA. Topiramate studies do show efficacy
but there is no approval for this condition [13–15]. Add-
itionally, a variety of behavioral medicine treatments, such
as biofeedback training and cognitive restructuring, are
available for these patients [16].
Do we need novel migraine preventive treatments?
Although there are many approved and unapproved pre-
ventive treatments for migraine, they are often insufficient
to manage migraineurs effectively, even in the right hands.
There are issues of efficacy, tolerance, safety, adherence,
pharmacophobia and nocebo response, all suggesting the
need for better treatments. There are several outcome
measures used in clinical trials to qualify the efficacy of
migraine prevention. The most common is a decrease in
migraine or headache days per month compared to base-
line, and the proportion of responders to the treatment,
defined as those patients that report more than a 50 % de-
crease in migraine days per month after a given treatment
(the 50 % responder rate). The number needed to treat
(NNT; defined as the number of patients who need a spe-
cific treatment to prevent one additional bad outcome,
e.g. a migraine attack) for responders varies from 4–6 in
several randomized trials for migraine prevention (indicat-
ing that 4–6 patients suffering from migraine must be
treated in order for one to reach a 50 % decrease in mi-
graine days per month). The decrease in migraine days
per month after extracting the placebo effect varies from
1.2–1.8 [17, 18]. This absolute improvement, not includ-
ing the placebo effect that indeed exists and improves
treatment outcomes in real life, looks very small; there is
clearly room for improvement. There is also evidence that
migraineurs are very sensitive to adverse events (AEs) of
preventive medications and more likely to withdraw from
treatment because of AEs in comparison to epileptics, as
one meta-analytic study with topiramate showed [19].
Generally, one out of five patients treated with any mi-
graine preventive pharmaceutical agent will discontinue
treatment because of tolerability and safety reasons [20],
as did one out of twenty patients treated with placebo in
randomized controlled studies [21]. In this context, a
medication’s safety profile matters significantly to migrai-
neurs and impacts adherence considerably [22].
Adherence is poor in migraine preventive treatments, as
in most conditions requiring chronic therapy. Only one
out of four patients complies with treatment in chronic
migraine when it is required for 6 months, and this de-
creases to one in five when treatment duration increases
to 1 year. Adherence is related to drug tolerability and effi-
cacy [23], once again indicating the need for novel and
better anti-migraine therapies.
Pharmacophobia refers to the fear of medication. Taken
together with the nocebo effect, which refers to the ex-
perience of AEs related to patients’ negative expectation
that a treatment will most likely harm instead of help,
these two concepts control treatment adherence and out-
come in migraine and other headaches significantly. It is
known that one out of twenty headache sufferers discon-
tinues treatment because of the nocebo effect [22]. For all
of these reasons, improved therapeutic approaches, in-
cluding non-pharmaceutical ones, should continue to
be researched.
Novel preventive anti-migraine treatments and interventions
In the last 10 years, several new acute care and prevent-
ive migraine treatments have surfaced, some of them re-
lated to the calcitonin gene-related peptide (CGRP). The
small molecule CGRP receptor antagonists have been ef-
fective, without evidence of vasoconstriction in animals,
but there have been issues of safety, thus far preventing
further development. In the last few years we have seen
the development of four monoclonal antibodies targeting
CGRP or its receptor (CGRP-mAbs). Phase 2 trials show
promising efficacy data with limited adverse events and
almost no serious adverse events.
Monoclonal antibodies to CGRP ligand and receptor
Although the small molecule agents that target the CGRP
receptor are still under investigation, the recent develop-
ment of humanized antibodies to CGRP and its receptor
appear more promising for three important reasons: they
are unlikely to cause liver toxicity or other serious AEs;
they are biological products with extreme specificity for
their target and very long half-lives, compared to oral
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medications; and they may have considerably better tol-
erability and safety profiles [24].
To demonstrate that CGRP-mAbs will be useful in
migraine treatment, four such antibodies have been
tested successfully in animal models and are currently
in phase 3 trials in the US [25–27]. The major concern
is that blocking CGRP, a potent and ubiquitous vasodilator,
may cause cardiovascular effects, including medication-
induced hypertension, interactions with the efficacy of
anti-hypertensive drugs and inhibition of ischemia-related
coronary vasodilatation [28]. Monoclonal antibodies may
cause biological effects within other organ systems. Infu-
sion and immunological reactions are also potential ad-
verse events [29]. Another important concern is the long
half-lives of mAbs, which prevent immediate clearance in
case of severe AEs [24]. Of course, this is also one of its
major benefits, as long half-lives prevent the need for fre-
quent dosing. Lastly, the possible development of neutral-
izing anti-drug antibodies may abolish the effectiveness of
the treatment, but this has not been a significant issue thus
far in the trials. To eliminate these concerns, several phase
1 studies have been conducted in humans for each of these
therapies and show that sustained CGRP inhibition is not
associated with hemodynamic or ECG changes, nor have
other significant safety concerns emerged [30, 31].
Four humanized, monoclonal antibodies are currently in
phase 3 trials for the prevention of episodic or chronic
migraine and even cluster headache: ALD403 (Alder
Biopharmaceutical, Bothell, WA, USA); LY2951742 (Eli
Lilly, Indianapolis, IN, USA); AMG 334 (Amgen, Cam-
bridge, UK); and TEV-48125 (Teva, Petah Tikva, Israel)
[32–36] The principal findings of these phase 2 studies
are summarized in Table 1. Published data are available
for three antibodies: LY2951742; ALD403; and TEV-48125
[32, 33, 35, 36]. Data for AMG 334 is based on a presen-
tation at the International Headache Society Congress
(IHC) in Valencia, in May 2015 [34]. Some CGRP anti-
bodies have been tested in patients suffering from episodic
migraine, others in a wider range of headache frequencies,
from high frequency episodic migraine to chronic migraine
(Table 1). The primary endpoint was common in all studies
of episodic migraine (change in migraine days per month
from baseline). TEV-48125 was also tested in chronic mi-
graine using a novel primary endpoint of decrease in the
total number of hours per month of headache at 3 months
versus baseline [36]. The different frequencies of migraine
in these studies, the different types of migraine and the dif-
ferent primary endpoints make it difficult to adequately
compare these treatments.
All four episodic migraine studies show the monoclo-
nal antibodies starting to work in 4 weeks versus pla-
cebo. The TEV-48125 study shows significance over
placebo in less than 1 week [36]. In Table 2, a compari-
son between CGRP monoclonal antibodies and currently
available oral treatments in the prevention of episodic
migraine [37] is presented. NNT are comparable. How-
ever, these comparisons merely present a rough idea of
comparability. Since each trial is different and there are
no head-to-head studies, no conclusions can be drawn.
Numbers needed to harm (NNH) appear to favor TEV-
48125, ALD403 and LY2951742. NNTs for treatment
discontinuation due to AEs and relative risks for AEs
favor LY2951742, ALD403 and TEV-48125 as well [37].
Adverse events specific to CGRP actions (e.g. hyperten-
sion and coronary vasodilatation) have not been an
issue in these trials. Lastly, the development of anti-
CGRP antibodies remains to be tested in long-term
follow-up studies. In the Teva trials, a few patients had
neutralizing antibodies even before starting the trial,
the number did not increase after the trial and no sig-
nificant problems developed in those patients. The
other trials had patients with more neutralizing auto-
antibodies with apparently no deleterious effects. Re-
sults from phase 2 studies in episodic migraine showed
that patients treated with either ALD403 or LY2951742
developed anti-CGRP222 antibodies within 24 weeks
(14 % and 18 %, respectively) [32, 33], indicating that
some will develop neutralizing auto-antibodies (NAbs).
Experience from biological agents used in multiple
sclerosis (MS) shows that about 15 % of patients de-
velop neutralizing auto-antibodies, which decreases
biological activity and consequently their therapeutic
action [38].
Adherence to treatment is a critical factor in migraine
management, but is often underuestimated [23, 39, 40].
Many patients who begin migraine prevention with oral
agents no longer take these medications 3–6 months after
they start them. One study shows that 73.4 %, 70.2 % and
67.6 % of 4,634 migraineurs who initiated migraine preven-
tion with antidepressants, anti-epileptics and beta-blockers,
respectively, were found non-adherent 6 months later [40].
More than a few factors power adherence, including toler-
ability and frequency of treatment administration, and both
favor CGRP-mAbs; but this has to be proven in long-term
follow-up studies.
Overall, CGRP-mAbs look like promising options for
migraine and chronic migraine prevention with impressive
responder rates, improved safety and tolerability, absence
of liver toxicity and long half-lives leading to infrequent
dosing. Depending on the results of phase 3 trials, these
therapies could become first-line in episodic and chronic
migraine prevention. No doubt they will be costly, but if
they are effective, prevent disability and frequent visits for
emergency care, they may be cost-effective.
Notably, oral CGRP receptor antagonists are still under
investigation for acute care and prevention of migraine,
with promising results. Telcagepant did not show efficacy
over placebo in women suffering from perimenstrual
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Table 1 Monoclonal antibodies target to CGRP pathway in clinical trials phase II for migraine prevention
Antibody Target Study size
population
(active vs.
placebo)
Inclusion criteria Mean baseline
MHD/28d
(active vs.
placebo)
Treatment
duration
(weeks)
Dose, root &
frequency
Primary
outcome
(change from
baseline)
Active vs. placebo
change of primary
outcome
50 %
responder
rate (NNT)
Dropout
ratio
Common AEs Anti-drug
antibodies
LY2951742
[33]
CGRP 218
(108 vs. 110)
Episodic migraine
(4–14 MHD/28d)
6.7 vs. 7.0 12 150 mg sc; every
2 weeks
MHD/28d
(at 9–12 weeks)
−4.2 vs. -3.0
(1.2 days difference,
p = 0.003)
70 % vs.
45 % (4.0)
12 % Erythema; Site
pain; infection;
abdominal pain
18.7 %
ALD403
[32]
CGRP 163
(81 vs. 82)
Episodic migraine
(5–14 MHD/28d)
8.4 vs. 8.8 12 1 g iv; once MHD/28d
(at 5–8 weeks)
−5.6 vs. -4.6 (1 day
difference, p = 0.03)
75 % vs.
54 % (4.7)
6.2 % Tooth abscess;
dizziness; ECG
changes; dry
mouth
14 %
TEV48125
[35]
CGRP 297 (96, 97
vs. 104)
Episodic migraine
(8–14 MHD/28d)
11.4 vs. 11.5 12 225 & 675 mg sc;
every 4 weeks
MHD/28d 2.64 days difference,
p < 0.001
59 % vs.
28 % (3.2)
9.1 % Injection site
discomfort;
redness
1 %
TEV48125
[36]
CGRP 264 (175 vs.
89, 3 arms)
Chronic Migraine 16.4 vs. 16.8
(157.7 vs.
169.1 hours/mo)
12 225/675 &
900 mg sc; every
4 weeks
HH/28d −67.5 vs. -37.1
(30.4 hrs difference,
p = 0.001)
NA 14.4 % Injection site;
pruritus
1 %
AMG334
[34]
CGRP
receptor
483 (4 arms) Episodic migraine 8.7 12 7, 21 & 70 mg sc;
every 4 weeks
MHD/28d
(at 9–12 weeks)
−3.4 vs. -2.28
(1.1 day difference,
p = 0.021)
47 % vs.
30 % (5.9)
NA Fatigue;
influenza;
nasopharyngiitis;
arthralgia; back
pain
NA
TEV48125: efficacy results for the higher dose used (675 mg in episodic migraine and 900 mg in chronic migraine) [35, 36]; AMG344: efficacy results for the dose of 70 mg [34]; MHD: Migraine Headache Days; HH:
Headache Hours; NNT: number needed to treat
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migraine [41], but in another placebo-controlled trial for
migraine prevention, telcagepant resulted in a larger reduc-
tion from baseline than placebo for mean monthly head-
ache days (month 1: 140 mg, −2.9; 280 mg, −3.1;
placebo, −1.7; P <0.05) and migraine/probable migraine
days (month 1: 140 mg, −2.7; 280 mg, −3.0; placebo, −1.6;
P <0.05) [42]. In both studies elevation of serum alanine
aminotransferase was observed in a proportion of pa-
tients (2.5 %, when the drug is taken daily), indicating
safety concerns.
Neurostimulation
Invasive and non-invasive central or peripheral neurosti-
mulation techniques have been developed by different
companies with encouraging results for various head-
ache disorders, including migraine and cluster headache.
Recently the Neuromodulation Appropriateness Consen-
sus Committee concluded that extracranial nerve stimu-
lation should be considered in the algorithmic treatment
of migraine [43]. To date there is evidence that only two
non-invasive techniques are effective in migraine pre-
vention: transcutaneous supraorbital and supratrochlear
nerve stimulation (tSNS) and vagus nerve stimulation
(VNS). Invasive techniques are also under investigation,
yet they target non-responders to the currently available
therapies in chronic migraine and in chronic cluster
headache; but will not discussed here, even though they
appear effective in early trials [44].
Transcutaneous supratrochlear nerve stimulation (tSNS)
The efficacy and safety of tSNS for prevention of episodic
migraine has been evaluated in a randomized, double-
blind, sham-controlled trial published in Neurology [45].
Sixty-seven patients were treated with daily tSNS or sham
sessions for 20 minutes per day for 3 months. The change
in migraine days per month from baseline was signifi-
cantly better in tSNS patients than in sham-treated pa-
tients (−2.06, P = 0.023 vs. −0.32, P = 0.608) and had a
50 % responder rate (38.1 % vs. 12.1 %, P = 0.023, NNT =
3.8). Importantly, the primary endpoint of change in mi-
graine days per month just missed significance in the
intention-to-treat group (P= 0.054) and was not significantly
different in per protocol analysis (P= 0.06) in the compari-
son between groups (tSNS and sham-treated). Rescue mi-
graine medication intake was significantly reduced in the
verum but not in the sham group. Notably, patients did not
report many AEs [45]. It should be noted that it was difficult
to completely blind this study. Although not reported in the
study, personal reports from several patients using the de-
vice indicated that the paresthesias were strong enough to
cause unblinding and discontinuation from the trial. In an
observational survey among 2,313 patients, 54.4 % were sat-
isfied with the treatment. Only 4.3 % of individuals reported
one or more AEs, such as local pain/intolerance to
paresthesia (2.03 %), arousal changes (0.82 %) and headache
after the stimulation (0.52 %). A transient local skin allergy
was seen only in 0.09 % [46]. In a second uncontrolled, ob-
servational study of patients suffering from episodic mi-
graine without aura, a 2-month treatment with Cefaly
(Cefaly Technology, Grâce-Hollogne, Belgium) significantly
reduced migraine days per month compared to the base-
line period, without reported AEs [47].
Transcutaneous vagal nerve stimulation (tVNS)
In a randomized, sham-controlled pilot study for prevention
of chronic migraine with transcutaneous vagal nerve stimu-
lation (tVNS) using the gammaCore stimulator (three daily
90-second stimulations for 2 months) the responder ratio
was 15 % (4 out of 26) in the verum group compared to zero
(none out of 23) in the sham-stimulated group (NNT= 6.7)
[48]. This beneficial effect was confirmed in the subsequent
open-label phase [49]. Besides neck muscle (platysma) con-
tractions in some patients, there were no significant AEs.
Apart from these preliminary data, further studies are
needed to determine the role of tVNS in migraine preven-
tion. Recent data indicate good efficacy for the symptomatic
treatment of both migraine and cluster headache, and also
for the prevention of cluster headache [50, 51].
Sphenopalatine ganglion stimulation
Sphenopalatine ganglion stimulation is under investiga-
tion for the symptomatic and preventive treatment of
Table 2 Comparison between CGRP monoclonal antibodies, transcutaneous supraorbital nerve stimulation and current available oral
treatments in the prevention of episodic migraine
Drug LY2951742
[33]
ALD403
[32]
TEV48125
[35]
AMG334
[34]
tSNS
[42]
Valproate
[37]
Topiramate
[37]
Propranolol
[37]
Amitriptyline
[37]
NNT 4 4.7 3.2 5.9 3.8 4 3 4 4
NNH 20 20 ∞ NA ∞ 7-14 2-17 NA NA
Relative risk for AE 1.07 1.09 1 NA 1 1.2 1.8 2.1 1.9
NNT for discontinuation due
to AE
∞ ∞ ∞ NA ∞ NA 16 16 19
tSNS: transcutaneous supraorbital nerve stimulation; NNT: number needed to treat; NNH: number needed to harm; AE: adverse event; NA: non applicable; ∞: NNH,
same percentage of patients experienced any adverse event in both placebo and drug treated patients; NNTs for discontinuation due to adverse events, no
patient treated with the drug discontinued because of adverse event
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both migraine and cluster headache. When used acutely for
attacks in patients with chronic cluster headache, many at-
tacks significantly improve within 15 minutes, which was
the primary endpoint. Some patients also experience a de-
crease in frequency of attacks over time. The device is avail-
able in Europe and has a CE mark (a CE mark is a logo
that is placed on medical devices to show they conform to
the requirements of the Medical Device Directive; it shows
that the device is fit for its intended purpose as stated and
meets legislation relating to safety; and it shows the product
can be freely marketed anywhere in the European Union
without further control). It is more invasive than tVNS,
since implantation of the device through the oral cavity
under general anesthesia is required [52].
Transcranial magnetic stimulation
There are data indicating that high-rate, repetitive trans-
cranial magnetic stimulation is effective in migraine pre-
vention [53], but further investigation is needed.
In general, these preliminary data of non-invasive neuro-
stimulation in migraine prevention and symptomatic treat-
ment of attacks in chronic cluster headache point towards a
safety advantage, but whether they will be efficacious enough
is yet to be determined. Additionally, neurostimulation may
be a much better treatment option for migraineurs that do
not stay on oral medications due to a variety of factors, such
as pharmacophobia and nocebo behaviors. There are many
studies of invasive implanted stimulators for chronic mi-
graine and other headaches that are not discussed here.
Conclusions
Migraine is a common, chronic neurovascular disorder of
the brain with cranial autonomic findings. It is characterized
by recurrent, severe attacks of headaches often associated
with other symptoms and much disability, as well as per-
sonal, familial and societal impact. Currently, there only are
a limited number of preventive treatments for migraine
worldwide, and they often are ineffective and cause AEs
leading to low retention rates. Better therapies are badly
needed. CGRP-mAbs to the ligand and receptor display at
least, if not greater, comparable efficacy to the currently
available oral therapies, with better safety data and perhaps
adherence in phase 2 trials. Neurostimulation also appears
promising, despite the limited evidence. Both monoclonal
antibodies and neurostimulation appear to offer effective,
novel management for migraine prevention and acute care
of chronic cluster headache. We look forward to further re-
sults of these above therapies.
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